Test Code: 1310

Diffuse Gastric Cancer Syndrome: CDH1 Gene Sequencing
Test code: 1310
Turnaround time: 5 weeks

CONDITION DESCRIPTION

Diffuse gastric cancer (DGC) is a genetic cancer susceptibility syndrome characterized by a high risk for stomach and lobular breast cancer and is inherited in an autosomal dominant pattern. Gastric cancers that occur in this syndrome are of the diffuse-type, as opposed to intestinal, and often have signet ring cells through the stomach wall causing thickening, without forming a discrete mass.

Women with a CDH1 pathogenic variant have a 39-52% lifetime risk for lobular breast cancer and a 63-93% risk of developing diffuse gastric cancer. Men have an estimated 40-67% lifetime risk of developing diffuse gastric cancer. Diffuse gastric cancer generally occurs before age 50 in CDH1 pathogenic variant carriers, though cases under the age of 18 have been reported with a family history of hereditary diffuse gastric cancer.

References:

  • GeneReviews.
  • Kaurah P, MacMillan A, et.al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360–72.
  • Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–53.
  • Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.

GENES
CDH1

INDICATIONS

This test is indicated for:

  • Confirmation of a clinical diagnosis of diffuse gastric cancer syndrome.

METHODOLOGY

PCR amplification of 16 exons contained in the CDH1 gene is performed on the patient’s genomic DNA. Direct sequencing of amplification products is performed in both forward and reverse directions, using automated fluorescence dideoxy sequencing methods. The patient’s gene sequences are then compared to a normal reference sequence. Sequence variations are classified as pathogenic variants, benign variants unrelated to disease, or variations of unknown clinical significance. Variants of unknown clinical significance may require further studies of the patient and/or family members. This assay does not interrogate the promoter region, deep intronic regions, or other regulatory elements, and does not detect large deletions.

DETECTION

Clinical Sensitivity: Unknown. Pathogenic variants in the promoter region, some pathogenic variants in the introns and other regulatory element pathogenic variants cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient’s biochemical phenotype.

Analytical Sensitivity: ~99%.

SPECIMEN REQUIREMENTS

Submit only 1 of the following specimen types

Type: Whole Blood
Specimen Requirements:
In EDTA (purple top) or ACD (yellow top) tube:
Infants (<2 years): 2-3 ml
Children (>2 years): 3-5 ml

Older Children & Adults: 5-10 ml.Specimen Collection and Shipping: Ship sample at room temperature with overnight delivery.

Type: Saliva
Specimen Requirements:
OrageneTM Saliva Collection kit (available through CEN4GEN) used according to manufacturer
instructions.
Specimen Collection and Shipping: Store sample at room temperature. Ship sample within 5 days of collection at room temperature with overnight delivery.

RELATED TESTS

  • Gastrointestinal and Colorectal Cancer: Sequencing Panel
  • Hereditary Cancer Syndrome: Sequencing Panel